Puma BioTech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 54.48 B

Revenue: As of FY2025 Q3, the actual value is USD 54.48 B, beating the estimate of USD 51 M.

EPS: As of FY2025 Q3, the actual value is USD 0.17, beating the estimate of USD 0.045.

EBIT: As of FY2025 Q3, the actual value is USD 10.02 B.

Segment Revenue

• Product Revenue, Net: $51.9 million for the three months ended September 30, 2025, compared to $56.1 million for the same period in 2024, primarily due to a decrease in product supply revenue to international licensees, partially offset by an increase in domestic sales.
• Royalty Revenue: $2.6 million for the three months ended September 30, 2025, compared to $24.4 million for the same period in 2024, primarily due to timing of sales made into China by sub-licensees.

Operational Metrics

• Net Income: $8.8 million for the three months ended September 30, 2025, compared to $20.3 million for the same period in 2024.
• Operating Costs and Expenses: $44.9 million for the three months ended September 30, 2025, compared to $58.5 million for the same period in 2024.
• Research and Development Expenses: $15.9 million for the three months ended September 30, 2025, compared to $12.6 million for the same period in 2024, primarily due to increased alisertib study activity.

Cash Flow

• Operating Cash Flow: $27.4 million for the nine months ended September 30, 2025, compared to $23.3 million for the same period in 2024.
• Investing Activities: Net cash used was $9.2 million for the nine months ended September 30, 2025, primarily due to the purchase of available-for-sale securities.
• Financing Activities: Net cash used was $33.9 million for the nine months ended September 30, 2025, primarily due to the payment of principal and exit fees on debt with Athyrium.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the development of alisertib, initially targeting small cell lung cancer and hormone receptor-positive breast cancer. The company also aims to sustain operations and commercialize neratinib successfully.
• Non-Core Business: The company is exploring additional marketing efforts and potential acquisitions of additional drug candidates, which may require additional funding.
• Priority: The company intends to satisfy near-term liquidity requirements through existing cash, cash equivalents, and marketable securities, along with proceeds from product sales, royalties, and sub-license milestone payments.